Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:14:05 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:EXEL from 2023-04-27 to 2024-04-26 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-16 16:05U:EXELNews ReleaseExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
2024-02-27 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in March
2024-02-14 08:30U:EXELNews ReleaseAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-06 16:05U:EXELNews ReleaseExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
2024-02-01 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in February
2024-01-25 08:00U:EXELNews ReleaseExelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
2024-01-23 16:05U:EXELNews ReleaseExelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
2024-01-22 17:00U:EXELNews ReleaseOpdivo ‚ ® (nivolumab) in Combination with CABOMETYX ‚ ® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
2024-01-18 16:05U:EXELNews ReleaseEuropean Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX ‚ ® (cabozantinib) Tablets
2024-01-07 16:00U:EXELNews ReleaseExelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
2024-01-02 16:05U:EXELNews ReleaseExelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
2023-12-07 16:05U:EXELNews ReleaseExelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
2023-12-04 08:02U:EXELNews ReleaseExelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
2023-12-04 08:00U:EXELNews ReleaseExelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
2023-12-04 08:00U:EXELNews ReleaseExelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
2023-11-21 16:05U:EXELNews ReleaseExelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
2023-11-10 09:00U:EXELNews ReleaseExelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
2023-11-01 16:05U:EXELNews ReleaseExelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-18 16:05U:EXELNews ReleaseExelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
2023-09-12 08:00U:EXELNews ReleaseExelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
2023-08-31 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in September
2023-08-24 08:00U:EXELNews ReleaseExelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
2023-08-23 16:30U:EXELNews ReleaseExelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
2023-08-21 01:00U:EXELNews ReleaseExelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
2023-08-01 16:05U:EXELNews ReleaseExelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-23 16:00U:EXELNews ReleaseExelixis, Inc. Announces Settlement of CABOMETYX ‚ ® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
2023-07-18 16:05U:EXELNews ReleaseExelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
2023-05-31 12:30U:EXELNews ReleaseFarallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis ¢ € ™ Board
2023-05-30 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in June
2023-05-09 16:05U:EXELNews ReleaseExelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-07 23:30U:EXELNews ReleaseFarallon Capital Management Comments on Successful Campaign for Change at Exelixis
2023-05-07 17:00U:EXELNews ReleaseExelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
2023-05-03 16:05U:EXELNews ReleaseExelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
2023-05-03 09:00U:EXELNews ReleaseFarallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
2023-05-01 17:08U:EXELNews ReleaseExelixis Files Definitive Proxy Statement and Mails Letter to Shareholders